CURRENT REPORT

Lotus Bio-Technology Development Corp.

(a Wyoming Corporation)

August 17, 2022

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.

August 3, 2022

Information required for compliance with the provisions of the OTC Markets, Inc.,

Pink Basic Disclosure Guidelines

(v.3.1 June 24, 2021)

Because we want to provide more meaningful and useful information, this Current Report may contain certain "forward-looking statements" (as such term is defined in Section 21E of the Securities Exchange Act of 1934, as amended). These statements reflect our current expectations regarding our possible future results of operations, performance, and achievements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, regulation of the Securities and Exchange Commission, and common law.

Wherever possible, we have tried to identify these forward-looking statements by using words such as "anticipate," "believe," "estimate," "expect," "plan," "intend," and similar expressions. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, these statements are subject to certain risks, uncertainties, and contingencies, which could cause our actual results, performance, or achievements to differ materially from those expressed in, or implied by, such statements. We have no obligation to update or revise any such forward-looking statements that may be made to reflect events or circumstances after the date of this Current Report.

Item 1. Departure of Directors or Principal Officers.

On August 3, 2022, Zoltan Nagy submitted his resignation as a director. His letter of resignation included a statement that his resignation was not as a result of any dispute with the Company.

Certification

I, Hoyt Christopher, President of Lotus Bio-Technology Development Corp., hereby certify that:

  1. I have reviewed the Issuer's Current Report dated August 17, 2022.
  2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements made, not misleading with respect to the period covered by this Current Report.

Date: August 17, 2022

/s/ Hoyt Christopher

Hoyt Christopher, President

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Lotus Bio-Technology Development Corp. published this content on 19 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2022 19:03:20 UTC.